Tetrud J W, Langston J W
California Parkinson's Foundation, San Jose.
Acta Neurol Scand Suppl. 1989;126:35-40. doi: 10.1111/j.1600-0404.1989.tb01780.x.
It is now well recognized that 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) can induce a syndrome in human and non-human primates similar to Parkinson's disease. This highly selective neurotoxin, which affects specific catecholaminergic nuclei in the brainstem, has provided an important new tool for the study of Parkinson's disease. In this article we review several specific areas related to current research on MPTP, including the question of disease progression, issues regarding the validity of the animal model induced by MPTP, the role of aging in regard to its neurotoxicity and Parkinson's disease, and new therapeutic strategies that have evolved from basic research with the compound. We conclude that both clinical and basic research stemming from the discovery of MPTP have provided valuable insights regarding both the cause and treatment of Parkinson's disease.
现已充分认识到，1-甲基-4-苯基-1,2,3,6-四氢吡啶（MPTP）可在人类和非人类灵长类动物中诱发一种类似于帕金森病的综合征。这种高度选择性的神经毒素会影响脑干中的特定儿茶酚胺能核团，为帕金森病的研究提供了一种重要的新工具。在本文中，我们回顾了与MPTP当前研究相关的几个特定领域，包括疾病进展问题、MPTP诱导的动物模型的有效性问题、衰老在其神经毒性和帕金森病方面的作用，以及从对该化合物的基础研究中发展而来的新治疗策略。我们得出结论，源于MPTP发现的临床和基础研究都为帕金森病的病因和治疗提供了有价值的见解。
